Overview

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Status:
Active, not recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL).

Phase:

Phase 2

Details

Lead Sponsor:

HUYA Bioscience International

Collaborator:

Quintiles, Inc.